started · updated
Dimerix finds human evidence for kidney disease target
Dimerix has obtained new human evidence supporting the biological rationale for its investigational kidney disease treatment, DMX-200. An independent analysis of 261 patients with focal segmental glomerulosclerosis (FSGS) linked heightened activity in the C-C chemokine receptor type 2 (CCR2) pathway to declining kidney function.
The study, presented at Kidney Week 2026, found that CCR2-associated gene activity was higher in FSGS kidney samples compared to healthy donor samples. Researchers also identified that urinary monocyte chemoattractant protein-1 (MCP-1) was associated with an increased risk of kidney failure. While these findings support the target being investigated in Dimerix’s ACTION3 trial, they do not establish clinical efficacy for DMX-200. The company has filed a provisional patent application regarding these findings.
Entities
Dimerix · Dr Sean Eddy · Nephrotic Syndrome Study Network · University of Michigan
Claims
What the coverage asserts, and how many sources carry each claim.
- [○ 1 SOURCE] The findings support the treatment target for DMX-200 but do not establish clinical efficacy. smallcaps.com.au
- [○ 1 SOURCE] The ACTION3 trial is fully recruited. smallcaps.com.au
- [○ 1 SOURCE] Urinary monocyte chemoattractant protein-1 (MCP-1) was associated with a greater risk of kidney function deterioration. smallcaps.com.au
- [○ 1 SOURCE] CCR2-associated gene activity was higher in FSGS kidney samples than in healthy donor samples. smallcaps.com.au
- [○ 1 SOURCE] An analysis of 261 patients with focal segmental glomerulosclerosis linked CCR2 activity to poorer outcomes. smallcaps.com.au
- [○ 1 SOURCE] Dimerix has filed a provisional patent application covering the findings. smallcaps.com.au
- [○ 1 SOURCE] Heightened activity of the C-C chemokine receptor type 2 (CCR2) pathway is associated with declining kidney function. smallcaps.com.au